doxorubicin-her2 antibody fragment congugate (ALZA)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Namedoxorubicin-her2 antibody fragment congugate (ALZA)
Drug Alias Nameanti-her2 immunoliposomes (ALZA)doxorubicin immunoliposome (ALZA)anti-her2 doxorubicin liposomes (ALZA)her2 antibody fragment congugated Doxil (ALZA)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionTopoisomerase II inhibitorsReceptor protein-tyrosine kinase erbB-2 modulatorsVirus DNA polymerase inhibitors
TargetsVirus DNA polymeraseReceptor protein-tyrosine kinase erbB-2Topoisomerase II
Therapy Area/IndicationsBreast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San Francisco
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of California San FranciscoAlza Corp
Active IndicationsN/A
Inactive IndicationsBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A